Iovance Biotherapeutics granted 43,150 stock options to 4 new employees on Dec. 18, 2025 as inducement grants.
On December 18, 2025, in San Carlos, California, Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) disclosed the approval of inducement stock options for four new non-executive employees. The options cover a total of 43,150 shares of the company's common stock. Iovance is a biotech firm specializing in creating and providing innovative polyclonal tumor infiltrating lymphocyte ("TIL") treatments for cancer patients.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments